Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
ViewAttendees 1

C5A - Quantitative clinical pharmacology of antibody drug conjugate development: challenges and opportunities

Wednesday, November 13, 2024
1:45 PM – 3:15 PM MST
Location: Canyon Ballroom

Disclosure(s):
Yan Feng, PhD: Genmab: Employment (Ongoing)
Shelly Wang, PhD: Gilead Sciences: Employment (Ongoing); Metrum Research Group: Employment (Terminated)
Katharina Wilkins, PhD: No financial relationships to disclose
Rudy Gunawan, PhD: No financial relationships to disclose
Yangbing Li, PhD: No financial relationships to disclose

Presentations:

  • 1:45 PM – 2:15 PM MST
    Mechanistic QSP modeling for a deeper understanding of ADC toxicities and combination effects with immunotherapies

    Speaker: Katharina Wilkins, PhD (she/her/hers) – Metrum Research Group

  • 2:15 PM – 2:45 PM MST
    Dose Optimization of ADCs

    Speaker: Rudy Gunawan, PhD – Pfizer

  • 2:45 PM – 3:15 PM MST
    Regulatory Experiences and Considerations for Model-Informed Approaches in Antibody-drug conjugates (ADCs) Drug Development

    Speaker: Yangbing Li, PhD – U.S. Food and Drug Administration